Pemphigus: A brief review

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 9, Issue 4, 2009, Pages 371-375

  Groves, Richard W ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DESMOCOLLIN; DESMOGLEIN 1; DESMOGLEIN 3; DESMOPLAKIN; GOLD COMPLEX; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID;

ACANTHOLYSIS; ANTIBODY TITER; B LYMPHOCYTE; BLISTER; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMATOUS PEMPHIGUS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERTENSION; HYPOGONADISM; IGA PEMPHIGUS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KERATINOCYTE; MOUTH ULCER; NONHUMAN; OSTEOPOROSIS; PARANEOPLASTIC PEMPHIGUS; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VEGETANS; PEMPHIGUS VULGARIS; REVIEW; RURAL AREA; SIDE EFFECT; TOPICAL TREATMENT; UNITED KINGDOM; WEIGHT GAIN; WOUND CARE;

EID: 70249127283     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.9-4-371     Document Type: Review

References (25)

1. Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: Population based cohort study. BMJ 2008;337:a180.
2. Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol 1980;116:1035-7.
3. Brenner S, Tur E, Shapiro J et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001;40:562-9.
4. Aoki V, Millikan RC, Rivitti EA et al. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc 2004;9:34-40.
5. Gazit E, Loewenthal R. The immunogenetics of pemphigus vulgaris. Autoimmun Rev 2005;4:16-20.
6. Tron F, Gilbert D, Joly P et al. Immunogenetics of pemphigus: An update. Autoimmunity 2006;39:531-9.
7. Capon F, Bharkhada J, Cochrane NE et al. Evidence of an association between desmoglein 3 haplotypes and pemphigus vulgaris. Br J Dermatol 2006;154:67-71.
8. Amagai M. Pemphigus vulgaris and its active disease mouse model. Curr Dir Autoimmun 2008;10:167-81.
9. Gniadecki R. Desmoglein autoimmunity in the pathogenesis of pemphigus. Autoimmunity 2006;39:541-7.
10. Harman KE, Gratian MJ, Seed PT et al. Diagnosis of pemphigus by ELISA: A critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 2000;25:236-40.
11. Harman KE, Seed PT, Gratian MJ et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001;144:775-80.
12. Sharma P, Mao X, Payne AS. Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of pemphigus. J Dermatol Sci 2007;48:1-14.
13. Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J Biol Chem 2007;282:13804-12.
14. Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn D. Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction. J Clin Invest 2005;115:3157-65.
15. Evangelista F, Dasher DA, Diaz LA, Prisayanh PS, Li N. E-cadherin is an additional immunological target for pemphigus autoantibodies. J Invest Dermatol 2008;128:1710-8.
16. Vu TN, Lee TX, Ndoye A et al. The patho-physiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol 1998;134:971-80.
17. Mouquet H, Drouot L, Charlionnet R et al. Proteomic analysis of the autoantibody response following immunization with a single autoantigen. Proteomics 2006;6:4829-37.
18. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004;9:29-33.
19. Anhalt GJ, Kim SC, Stanley JR et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729-35.
20. Mentink LF, Mackenzie MW, Toth GG et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006;142:570-6.
21. Beissert S, Werfel T, Frieling U et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006;142:1447-54.
22. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9.
23. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52.
24. Barnadas M, Roe E, Brunet S et al. Therapy of paraneoplastic pemphigus with rituximab: A case report and review of literature. J Eur Acad Dermatol Venereol 2006;20:69-74.
25. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Groebeler M. Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects. Br J Dermatol 2007;156:352-6.